Plasmonic photothermal therapy of atherosclerosis with nanoparticles: long-term outcomes and safety in NANOM-FIM trial.

Aim: The safety options in nanomedicine raise an issue of the optimal niche at the real-world clinical practice.

Methods: This is an observational prospective cohort analysis of the 5-year clinical outcomes at the intention-to-treat population (nano vs ferro vs stenting; n = 180) of NANOM first-in-man trial (NCT01270139).

Results: Mortality (6 vs 9 vs 10 cases of cardiac death in groups, p < 0.